@article{3219867,
    title = "Nondetectable Prostate Carcinoma (pT0) after Radical Prostatectomy: A Narrative Review",
    author = "Kalampokis, N. and Grivas, N. and Karavitakis, M. and Leotsakos, I. and Katafigiotis, I. and Moschovas, M.C. and van der Poel, H. and European Association of Urology (EAU) Young Academic Urologists (YAU) Robotic Urology Working Group",
    journal = "Current Oncology",
    year = "2022",
    volume = "29",
    number = "3",
    pages = "1309-1315",
    publisher = "MDPI",
    issn = "1198-0052",
    doi = "10.3390/curroncol29030111",
    keywords = "Article;  biochemical progression free survival;  biochemical recurrence;  cancer growth;  cancer prognosis;  cancer recurrence;  cancer registry;  cancer size;  cancer staging;  cancer surgery;  castration resistant prostate cancer;  controlled study;  follow up;  Gleason score;  histology;  hormonal therapy;  human;  human tissue;  incidence;  male;  narrative;  neoadjuvant therapy;  nuclear magnetic resonance imaging;  oncology;  outcome assessment;  progression free survival;  prostate biopsy;  prostate cancer;  prostate carcinoma;  prostate volume;  prostatectomy;  questionnaire;  systematic review;  transurethral resection;  carcinoma;  pathology;  prostate;  prostate tumor;  prostatectomy, Carcinoma;  Humans;  Male;  Neoplasm Staging;  Prostate;  Prostatectomy;  Prostatic Neoplasms",
    abstract = "(1) Background: Following radical prostatectomy (RP), the absence of a demonstrable tumor on the specimen of a previously histologically proven malignancy is known as the pT0 stage. The aim of our present study is to perform a narrative review of current literature in order to determine the frequency and oncological outcomes in patients with pT0 disease. (2) Methods: A narrative review of all available literature was performed. (3) Results: The incidence of pT0 ranges between 0.07% and 1.3%. Predictors of the pT0 stage are only a single biopsy core with low-grade cancer, a cancer length not exceeding 2 mm and a high prostate volume. Biochemical recurrence ranges between 0 and 11%. (4) Conclusions: The absence of malignancy in the RP specimen despite a previous positive biopsy is a rare and unpredictable finding. Although the prognosis is considered to be excellent in most of the cases, a continued close follow-up is warranted. © 2022 by the authors. Licensee MDPI, Basel, Switzerland."
}